Androgen receptor-independent prostate cancer: an emerging clinical entity.

Androgen receptor-independent prostate cancer: an emerging clinical entity.

Cancer Biol Ther. 2018 Jan 15;:0

Authors: Sahin I, Mega AE, Carneiro BA

Abstract
Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer particularly in castration resistance stage by targeting these pathways. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and possible clinical impact of these studies in the near future in castration resistance prostate cancer.

PMID: 29333925 [PubMed - as supplied by publisher]

http://ift.tt/2DDgaZE